Female Sexual Dysfunction - Pipeline Review, H1 2020
Female Sexual Dysfunction - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2020, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 3, 7, 1, 1, 5 and 3 respectively.
Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2020, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 3, 7, 1, 1, 5 and 3 respectively.
Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Applied Biology Inc
Better Life Pharmaceuticals Inc
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
H. Lundbeck AS
Harrow Health Inc
Ivix Ltd
Kuhnil Pharmaceutical Co Ltd
M et P Pharma AG
Re-Pharm Ltd
S1 Biopharma Inc
TherapeuticsMD Inc
Female Sexual Dysfunction - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estradiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKW-00GA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Sexual Dysfunction - Dormant Projects
Female Sexual Dysfunction - Discontinued Products
Female Sexual Dysfunction - Product Development Milestones
Featured News & Press Releases
Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
Dec 11, 2019: Dar? Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada
Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
Oct 08, 2019: Mayfield Pharmaceuticals to Present update on lidocaine at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
Sep 24, 2019: TherapeuticsMD announces multiple presentations related to IMVEXXY at the 2019 Annual Meeting of the North American Menopause Society
Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
Jun 17, 2019: Dar? Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans
Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time
Mar 18, 2019: Dare Bioscience to present update on Sildenafil Cream at 31st Annual ROTH Conference
Jan 04, 2019: S1 Biopharma announces expanded analysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting
Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder
Nov 29, 2018: Dare Bioscience announces initiation of content validity study for Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Nov 27, 2018: Dare Bioscience Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Applied Biology Inc
Better Life Pharmaceuticals Inc
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
H. Lundbeck AS
Harrow Health Inc
Ivix Ltd
Kuhnil Pharmaceutical Co Ltd
M et P Pharma AG
Re-Pharm Ltd
S1 Biopharma Inc
TherapeuticsMD Inc
Female Sexual Dysfunction - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estradiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKW-00GA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Sexual Dysfunction - Dormant Projects
Female Sexual Dysfunction - Discontinued Products
Female Sexual Dysfunction - Product Development Milestones
Featured News & Press Releases
Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
Dec 11, 2019: Dar? Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada
Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
Oct 08, 2019: Mayfield Pharmaceuticals to Present update on lidocaine at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
Sep 24, 2019: TherapeuticsMD announces multiple presentations related to IMVEXXY at the 2019 Annual Meeting of the North American Menopause Society
Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
Jun 17, 2019: Dar? Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans
Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time
Mar 18, 2019: Dare Bioscience to present update on Sildenafil Cream at 31st Annual ROTH Conference
Jan 04, 2019: S1 Biopharma announces expanded analysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting
Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder
Nov 29, 2018: Dare Bioscience announces initiation of content validity study for Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Nov 27, 2018: Dare Bioscience Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Female Sexual Dysfunction, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Female Sexual Dysfunction - Pipeline by Applied Biology Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Better Life Pharmaceuticals Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2020
Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2020
Female Sexual Dysfunction - Pipeline by H. Lundbeck AS, H1 2020
Female Sexual Dysfunction - Pipeline by Harrow Health Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Ivix Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2020
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H1 2020
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H1 2020
Female Sexual Dysfunction - Dormant Projects, H1 2020
Female Sexual Dysfunction - Dormant Projects, H1 2020 (Contd..1), H1 2020
Female Sexual Dysfunction - Discontinued Products, H1 2020
Number of Products under Development for Female Sexual Dysfunction, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Female Sexual Dysfunction - Pipeline by Applied Biology Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Better Life Pharmaceuticals Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2020
Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2020
Female Sexual Dysfunction - Pipeline by H. Lundbeck AS, H1 2020
Female Sexual Dysfunction - Pipeline by Harrow Health Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Ivix Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2020
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H1 2020
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H1 2020
Female Sexual Dysfunction - Dormant Projects, H1 2020
Female Sexual Dysfunction - Dormant Projects, H1 2020 (Contd..1), H1 2020
Female Sexual Dysfunction - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Female Sexual Dysfunction, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Applied Biology Inc
Better Life Pharmaceuticals Inc
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
H. Lundbeck AS
Harrow Health Inc
Ivix Ltd
Kuhnil Pharmaceutical Co Ltd
M et P Pharma AG
Re-Pharm Ltd
S1 Biopharma Inc
TherapeuticsMD Inc
Number of Products under Development for Female Sexual Dysfunction, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Applied Biology Inc
Better Life Pharmaceuticals Inc
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
H. Lundbeck AS
Harrow Health Inc
Ivix Ltd
Kuhnil Pharmaceutical Co Ltd
M et P Pharma AG
Re-Pharm Ltd
S1 Biopharma Inc
TherapeuticsMD Inc
